Rohto Pharmaceutical's Earnings May Beat Guidance on Sales Momentum -- Market Talk

0510 GMT - Rohto Pharmaceutical's earnings for this fiscal year may beat its full-year guidance on strong sales momentum for its mainstay brands in Japan and overseas, Nomura analysts say in a research report. Its earnings are likely to stay robust as Nomura sees tailwinds for the pharmaceutical company's distinctive high-quality, affordable products from growth in the dermocosmetics market and consumers trading down in response to inflation. The brokerage lifts this fiscal year's operating-profit forecast for the Japanese company to 46.5 billion yen from Y45.7 billion. It raises the stock's target price to 3,650.0 yen from Y3,300.0 with an unchanged buy rating. Shares are 0.4% lower at Y2,791.5. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

September 11, 2026 01:10 ET (05:10 GMT)